Cargando…
Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
Although around 80% of endometrial cancers are diagnosed at early stages and present with a 5-year survival rate exceeding 95%, patients with advanced and recurrent disease show a poor prognosis and low response rates to standard chemotherapy. In the era of targeted therapy, the great advances in th...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356971/ https://www.ncbi.nlm.nih.gov/pubmed/32503218 http://dx.doi.org/10.3390/jcm9061721 |